DALLAS, Sept. 8, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring drug maker SciClone Pharmaceuticals Inc. (Nasdaq:SCLN). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on SciClone Pharmaceuticals Inc. (Nasdaq:SCLN) should be of particular interest to other biotechnology companies: Amgen Inc. (Nasdaq:AMGN), Schering-Plough Corp. (NYSE:SGP), Vertex Pharmaceuticals Inc. (Nasdaq:VRTX) and InterMune Inc. (Nasdaq:ITMN).
It is available at: http://www.stockpreacher.com/n/SCLN
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
SciClone Pharmaceuticals Inc. (SCLN) is a global biopharmaceutical company engaged in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases. The Company's primary product ZADAXIN, its own brand of thymalfasin or thymosin alpha 1, is sold in more than 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers, and as a vaccine adjuvant in China. The Company is pursuing regulatory approval for DC Bead(TM) as an embolic agent for the treatment of liver cancer.
In the report, the analyst notes:
"Aside from growth opportunities in China and Vietnam, the Company also looks to develop Zadaxin in certain countries as an enhancer of novel H1N1 flu vaccines for immune-compromised populations. SCLN CEO Friedhelm Blobel, Ph.D., stated that 'this plan entails many uncertainties, therefore we have not reflected additional sales or earnings in our updated 2009 guidance but we are building inventories to address the potential increased demand associated with this difficult healthcare situation.'
"Following its robust financial results for the second quarter of 2009, the Company anticipates a revenue increase of approximately 28% to 31%, or between $69 million and $71 million, for the rest of 2009, although quarterly sales growth is expected to return to levels more consistent with its established business. With its R&D focus going forward, the Company expects to increase expenses in the second half of 2009 associated with H1N1 animal and, potentially, human studies; timing of other clinical development expenses; and costs of in-licensing products for China."
To read the entire report visit: http://www.stockpreacher.com/n/SCLN
See what investors are saying about these stocks at: http://www.stockhideout.com/
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.